AstraZeneca PLC (AZN)vsDocGo Inc (DCGO)
AZN
AstraZeneca PLC
$188.41
+1.47%
HEALTHCARE · Cap: $284.30B
DCGO
DocGo Inc
$0.49
-1.91%
HEALTHCARE · Cap: $54.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 19932% more annual revenue ($60.44B vs $301.71M). AZN leads profitability with a 17.2% profit margin vs -62.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DCGO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Margin of Safety
+53.4%
Fair Value
$1.56
Current Price
$0.49
$1.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while DCGO is a turnaround play — different risk/reward profiles.
DCGO carries more volatility with a beta of 1.00 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.2% margins and 12.5% revenue growth. DCGO offers better value entry with a 53.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is an innovative mobile healthcare service provider that enhances patient access and optimizes healthcare delivery through its advanced logistics and telehealth solutions. Specializing in urgent care, diagnostic testing, and health screenings, DocGo addresses critical healthcare needs across various settings while significantly improving patient experiences. With a commitment to innovation and expanding healthcare accessibility, the company stands out in the rapidly evolving healthtech sector, positioning itself as a compelling investment opportunity for institutional investors seeking both sustainable growth and positive social impact.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?